journal
MENU ▼
Read by QxMD icon Read
search

Asia-Pacific Journal of Clinical Oncology

journal
https://www.readbyqxmd.com/read/28198155/sunrise-in-melanoma-management-time-to-focus-on-melanoma-burden-in-asia
#1
John Wen-Cheng Chang, Jun Guo, Chia-Yen Hung, Si Lu, Sang Joon Shin, Richard Quek, Anthony Ying, Gwo Fuang Ho, Huu Sau Nguyen, Boman Dhabhar, Virote Sriuranpong, Maria Luisa Tiambeng, Nugroho Prayogo, Naoya Yamazaki
No abstract text is available yet for this article.
February 15, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28181415/a-phase-ii-trial-of-concurrent-chemotherapy-with-intravenous-cisplatin-and-vinorelbine-and-radiotherapy-followed-by-consolidation-chemotherapy-with-oral-vinorelbine-in-locally-advanced-non-small-cell-lung-cancer-nsclc-the-concave-study
#2
Brett Gm Hughes, Elizabeth Ahern, Margot Lehman, Gary Pratt, Margaret Dauth, Wendy Pritchard, Leesa Wockner, Keith Horwood
AIM: Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study. METHODS: Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/m(2) and vinorelbine IV 20 mg/m(2) on days 1, 8, 22 and 29 concurrent with thoracic radiotherapy of 60 Gy in 30 fractions...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28181405/epidemiology-of-breast-cancer-in-indian-women
#3
REVIEW
Shreshtha Malvia, Sarangadhara Appalaraju Bagadi, Uma S Dubey, Sunita Saxena
Breast cancer has ranked number one cancer among Indian females with age adjusted rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000 women. Data reports from various latest national cancer registries were compared for incidence, mortality rates. The age adjusted incidence rate of carcinoma of the breast was found as high as 41 per 100,000 women for Delhi, followed by Chennai (37.9), Bangalore (34.4) and Thiruvananthapuram District (33.7). A statistically significant increase in age adjusted rate over time (1982-2014) in all the PBCRs namely Bangalore (annual percentage change: 2...
February 9, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124437/presence-of-pleural-effusion-is-associated-with-a-poor-prognosis-in-patients-with-epidermal-growth-factor-receptor-mutated-lung-cancer-receiving-tyrosine-kinase-inhibitors-as-first-line-treatment
#4
Tso-Fu Wang, Sung-Chao Chu, Jen-Jyh Lee, Gee-Gwo Yang, Wei-Han Huang, En-Ting Chang, Tissot Low, Yi-Feng Wu, Ruey-Ho Kao, Chih-Bin Lin
AIM: This study was conducted to evaluate the effect of clinical factors on the treatment outcomes of lung cancer patients with active epidermal growth factor receptor (EGFR) mutations treated by first-line tyrosine kinase inhibitors (TKIs). METHODS: Patients of stage IIIb or IV lung adenocarcinoma harboring mutated EGFR were enrolled between March 2010 and June 2014 and followed up until December 2015. The effects of various clinical features, such as age, sex, smoking history, EGFR mutation types, TKIs used, presence of pleural effusion, metastatic sites on progression-free survival (PFS) and overall survival (OS), were analyzed retrospectively...
January 26, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124500/efficacy-safety-and-pharmacokinetics-of-subcutaneous-azacitidine-in-taiwanese-patients-with-higher-risk-myelodysplastic-syndromes
#5
Wen-Chien Chou, Su-Peng Yeh, Liang-Tsai Hsiao, Sheng-Fung Lin, Yeu-Chin Chen, Tsai-Yun Chen, Eric Laille, Anoula Galettis, Qian Dong, Steve Songer, C L Beach
AIM: Clinical and pharmacokinetic effects of azacitidine in higher-risk myelodysplastic syndromes were established in mainly Caucasian populations. Because of inter-ethnic genotype variability of drug-metabolizing enzymes, it is important to evaluate azacitidine in populations expected to use the drug. METHODS: In this single-arm study, Taiwanese patients with higher-risk myelodysplastic syndromes received azacitidine 75 mg/m(2) /day for 7 days/28-day cycle for up to six cycles...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28124495/very-high-risk-prostate-cancer-stratification-by-outcomes-of-radiotherapy-and-long-term-androgen-deprivation-therapy
#6
Natsuo Tomita, Norihito Soga, Yuji Ogura, Takumi Kageyama, Takeshi Kodaira
AIM: The definition of very high-risk (VHR) prostate cancer is currently based on the study of radical prostatectomy. We aimed to identify a suitable definition for VHR group following external beam radiation therapy (EBRT) and long-term androgen-deprivation therapy (ADT). METHODS: This retrospective study included 356 high-risk patients treated with EBRT and long-term ADT. A median follow-up time was 68 months. At first, associations of previously described prognostic factors with biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS) and prostate cancer-specific survival (CSS) were examined...
January 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28120376/administrative-data-provide-vital-research-evidence-for-maximizing-health-system-performance-and-outcomes
#7
David Roder, Elizabeth Buckley
Although the quality of administrative data is frequently questioned, these data are vital for health-services evaluation and complement data from trials, other research studies and registries for research. Trials generally provide the strongest evidence of outcomes in research settings but results may not apply in many service environments. High-quality observational research has a complementary role where trials are not applicable and for assessing whether trial results apply to groups excluded from trials...
January 24, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28101911/comparison-of-cbv-beam-and-beac-high-dose-chemotherapy-followed-by-autologous-hematopoietic-stem-cell-transplantation-in-non-hodgkin-lymphoma-efficacy-and-toxicity
#8
Youwu Shi, Peng Liu, Shengyu Zhou, Jianliang Yang, Xiaohong Han, Xiaohui He, Changgong Zhang, Lin Gui, Yan Qin, Sheng Yang, Liya Zhao, Jiarui Yao, Bo Jia, Shuxiang Zhang, Yan Sun, Yuankai Shi
AIM: Limited data are available to guide the choice of conditioning regimen before autologous hematopoietic stem cell transplantation (AHSCT) for patients with lymphoma. METHODS: We analyzed 129 non-Hodgkin lymphoma patients who underwent AHSCT from 1996 to 2013 using the most common regimens: CBV (cyclophosphamide, carmustine and etoposide; n = 16), BEAM (carmustine, etoposide, cytarabine and melphalan; n = 36) and BEAC (carmustine, etoposide, cytarabine and cyclophosphamide; n = 77)...
January 19, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28078806/prognostic-factors-of-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombosis-treated-with-transcatheter-arterial-chemoembolization
#9
Hongyuan Liang, Peng Cui, Qiyong Guo, Xiaonan Mao, Feng Wen, Wei Sun, Ming Shan, Zaiming Lu
AIM: To investigate the factors that influence survival of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) following transarterial chemoembolization (TACE). METHODS: Retrospectively enrolled HCC patients with PVTT (n = 57). Patients received TACE, and the local tumor response was evaluated by modified response evaluation criteria in solid tumor (mRECIST). Overall survival and disease progression were evaluated using Kaplan-Meier survival curves...
January 12, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28029222/role-of-adjuvant-chemotherapy-in-t2n0m0-periampullary-cancers
#10
Vikas Ostwal, Caleb Harris, Bhawna Sirohi, Mahesh Goel, Munita Bal, Sadhana Kannan, Shailesh V Shrikhande
AIMS: Surgery is the only modality that offers cure for periampullary adenocarcinoma. However, surgery alone results in failure in 60% of patients. Studies have shown some benefits of chemotherapy in node positive and higher tumor stage patients. We sought to determine the role of adjuvant chemotherapy in early tumors with uninvolved nodes. METHODS: A retrospective analysis of a prospectively maintained database of patients resected of periampullary tumors from 2007 to 2014 was performed...
December 28, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28028915/apatinib-in-gastric-carcinoma-a-case-report-of-partial-response-for-first-line-treatment-in-advanced-disease
#11
Yaping Wang, Minghong Bi, Haoran Zhang, Zhenyuan Gao, Hairong Zhou, Shu Chang
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, with a gradual increasing incidence throughout the world. Mostly GC is diagnosed in its late stage. To date, there is no usable standardized treatment regimen for patients with advanced GC. Apatinib mesylate, small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), has been approved as third-line treatment for patients with advanced gastric adenocarcinoma in China, October, 2014. Till now, there is no case report about apatinib as first-line treatment for patients with advanced GC in literature...
December 28, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28008715/human-epidermal-growth-factor-receptor-2-status-of-gastric-cancer-patients-in-asia-results-from-a-large-multicountry-study
#12
Nirmala Pathmanathan, Jing-Shu Geng, Wencai Li, Xiu Nie, Januario Veloso, John Wang, Julie Hill, Philip Mccloud, Michael Bilous
AIM: Current estimates of the human epidermal growth factor receptor 2 (HER2)-positivity rate in gastric cancer vary widely in the literature, and there are limited data from countries in Asia. The primary aim of this study was to conduct a clinical audit of laboratories across seven countries in Asia to determine the incidence of HER2-positive gastric cancer in this region. METHODS: Pathologists were asked to collect data on patient gender, age, cancer site, specimen type, tumor spread, type and grade, HER2 test results, including protein and/or gene copy enumeration, and final HER2 status on consecutive gastric cancer cases tested for HER2 in their laboratory over a 2-year period...
December 23, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004883/afatinib-successfully-treated-leptomeningeal-metastasis-during-erlotinib-treatment-in-a-patient-with-egfr-mutant-exon18-g719s-lung-adenocarcinoma-as-a-second-line-chemotherapy
#13
Motohiro Tamiya, Takayuki Shiroyama, Takashi Nishihara, Takuji Nishida, Manabu Hayama, Ayako Tanaka, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Tomonori Hirashima
Exon18 mutations are detected in 3.6% of epidermal growth factor receptor mutations. Exon 18 mutations as driver mutations have higher sensitivities in vitro to second-generation (G)-tyrosine kinase inhibitors (TKIs) than to first G- and third G-TKIs at clinically relevant doses. In clinical trial, first G-TKIs have moderate but insufficient efficacy, and afatinib was more active in uncommon epidermal growth factor receptor mutations. Here, we present a case of a woman who was initially prescribed erlotinib for lung adenocarcinoma with an exon18 mutation...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004882/the-current-practice-preparedness-and-educational-preparation-of-oncology-professionals-to-provide-spiritual-care
#14
Ganessan Kichenadasse, Linda Sweet, Ann Harrington, Shahid Ullah
AIM: Limited data are available on how spiritual needs of patients with cancer care are addressed by Australian oncologists. The objectives of this study were to explore the current practice, preparedness and education of Australian oncologists and oncology trainees on the provision of spiritual care for their patients with cancer. METHODS: Participants were recruited through oncology professional organizations and data collected through an anonymous online survey using a validated questionnaire...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004881/efficacy-and-toxicity-of-pacebom-chemotherapy-in-relapsed-refractory-aggressive-lymphoma-in-the-rituximab-era
#15
Babak Tamjid, Joseph Mckendrick, Anthony Schwarer, Rowan Doig, Philip James, Patrick Hosking, Eliza A Hawkes
AIM: Relapsed/refractory (R/R) aggressive lymphoma outcomes are poor. There is no standard treatment. PACEBOM (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) has shown efficacy for several lymphoma subtypes in published reports. We evaluate PACEBOM+/-rituximab for R/R aggressive lymphomas in this millennium. METHODS: In this retrospective, single-center study, R/R aggressive lymphoma patients who received PACEBOM or its derivatives were identified from the pharmacy database...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004526/exercise-therapy-in-oncology-rehabilitation-in-australia-a-mixed-methods-study
#16
Amy M Dennett, Casey L Peiris, Nora Shields, Delwyn Morgan, Nicholas F Taylor
AIM: Oncology rehabilitation improves outcomes for cancer survivors but little is known about program availability in Australia. The aims of this study were: to describe oncology rehabilitation programs in Australia: determine whether the exercise component of programs is consistent with guidelines: and to explore barriers and facilitators to program implementation. METHODS: A sequential, explanatory mixed-methods study was completed in two phases: (1) a survey of Australian oncology rehabilitation programs; and (2) purposively sampled follow-up semistructured interviews with senior clinicians working in oncology rehabilitation who were involved with exercise prescription...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28004512/a-rapid-access-clinic-to-improve-delivery-of-ambulatory-care-to-cancer-patients
#17
James C Kuo, Madhawa De Silva, Chandra Diwakarla, Desmond Yip
BACKGROUND: Cancer patients may find it challenging to access timely advice and care. We evaluated the improvement in delivering ambulatory care in establishing a Rapid Assessment Clinic (RAC) in a cancer center. METHODS: Patients receiving chemotherapy who presented for assessment at the RAC from September 2013 to June 2014 were included for review. Patient demographics, tumor characteristics, presenting complaints, time to assessment, total time spent at the RAC and assessment outcome were extracted...
December 22, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27981760/infliximab-for-ipilimumab-induced-colitis-a-series-of-13-patients
#18
Nadine T Hillock, Sharryn Heard, Ganessan Kichenadasse, Catherine L Hill, Jane Andrews
OBJECTIVE: To review the outcomes of metastatic melanoma patients treated with infliximab for severe steroid-refractory colitis secondary to ipilimumab therapy. BACKGROUND: Immune-related colitis is a known potential adverse effect of ipilimumab, that causes significant morbidity and extended hospital stays. There are limited outcome data for patients treated with infliximab for ipilimumab-induced colitis refractory to corticosteroids. Management guidelines have been developed based on case study evidence only...
December 16, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27981753/association-between-genetic-polymorphisms-involved-in-the-hypoxia-inducible-factor-pathway-and-lung-cancer-risk-a-case-control-study-in-japan
#19
Yuzo Yamamoto, Chikako Kiyohara, Saiko Ogata-Suetsugu, Naoki Hamada, Yoichi Nakanishi
AIM: Hypoxia-inducible factor (HIF) contributes to the adaptation of tumor cells to hypoxic conditions, so genetic polymorphisms involved in this pathway may affect cellular response to hypoxia and be associated with cancer risk. Thus, we examined the association between the lung cancer risk and genetic polymorphisms involved in the HIF pathway. METHODS: This case-control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of HIF1A rs11549467, HIF1A rs11549465, HIF1A rs2057482, HIF2A rs13419896 and vascular endothelial growth factor A (VEGFA) rs833061 on the risk of lung cancer using TaqMan real-time PCR assay...
December 16, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27966288/an-analysis-of-incidental-and-symptomatic-pulmonary-embolism-pe-in-medical-oncology-patients
#20
D A Thaker, E Douglas, J Blazak, W Xu, B Hughes, M Burge, K Steinke, D Wyld
AIM: To determine the incidence of symptomatic versus incidental pulmonary embolism (PE) in oncology patients, characterize the nature and extent of incidental PE and the factors contributing to diagnosis. METHODS: Specialized web search engine was used to identify oncology patients with positive imaging studies for PE. PE identified at staging CT scans were classified as incidental PEs, whereas PE diagnosed by CTPA/VQ scan were classified as symptomatic PEs. RESULTS: A total of 111 patients with PE were identified over the period of three years...
December 14, 2016: Asia-Pacific Journal of Clinical Oncology
journal
journal
40999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"